Kornimate/medical-research-clean huggingface dataset:
vaccine therapy and ganciclovir in treating patients with mesothelioma

Conditions: Malignant Mesothelioma

Summary: rationale: ganciclovir may ease some of the side effects of cancer treatment. vaccines made from a person's modified malignant mesothelioma cells may make the cancer more sensitive to ganciclovir. purpose: phase i trial to study the effectiveness of vaccine therapy plus ganciclovir in treating patients who have stage i, stage ii, or stage iii malignant mesothelioma.

objectives: i. determine the safety and side effects of intrapleurally administered pa-1-stk modified ovarian carcinoma vaccine and ganciclovir in patients with stage i, ii, or iii malignant mesothelioma. ii. determine the maximum tolerated dose and dose limiting toxicities of this vaccine in these patients. iii. determine the immunologic response to this treatment regimen in these patients. iv. determine the intrapleural pharmakokinetics of ganciclovir in these patients. outline: this is a dose escalation study of pa-1-stk modified ovarian carcinoma vaccine. patients receive pa-1-stk modified ovarian carcinoma vaccine intrapleurally on day 1 followed by ganciclovir iv over 1 hour for 7 days beginning on day 1. patients in the first 2 cohorts receive 1 course of treatment only. in all subsequent cohorts, treatment repeats every 3 weeks for a total of 3 courses in the absence of disease progression or unacceptable toxicity. cohorts of 3 patients receive escalating doses of pa-1-stk modified ovarian carcinoma vaccine until the maximum tolerated dose is determined. projected accrual: a total of 3-16 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed stage i, ii, or iii malignant mesothelioma must have adequate pleural space in which to place chest tube or catheter patient characteristics: age: not specified performance status: ecog 0-1 life expectancy: not specified hematopoietic: hematocrit greater than 30% wbc greater than 4,000/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin normal sgot and alkaline phosphatase less than 1.5 times normal renal: creatinine less than 1.5 mg/dl creatinine clearance greater than 50 ml/min cardiovascular: no significant history of heart disease no frequent angina no myocardial infarction within the past 6 months no congestive heart failure requiring daily treatment pulmonary: no evidence of moderate to severe pulmonary disease (i.e., fev1 less than 40% predicted) other: no prior malignancy except squamous or basal cell carcinoma of the skin no patients with childbearing potential prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 6 weeks since prior chemotherapy endocrine therapy: no concurrent steroid treatment radiotherapy: at least 6 weeks since prior radiotherapy surgery: not specified

Keywords: stage ia malignant mesothelioma stage ib malignant mesothelioma stage ii malignant mesothelioma stage iii malignant mesothelioma
breathe: slow paced breathing to lower blood pressure

Conditions: High Blood Pressure

Summary: the purpose of this study is to investigate the nature of the physiological reasons for the decreases in resting blood pressure that can result from systematic practice of computer-guided breathing exercises or meditative relaxation.

in this randomized clinical trial, persons with moderately elevated blood pressure were trained in either computer-guided breathing exercises or meditative relaxation to breathing. the computer-guided breathing exercise involves listening to tones of ascending and descending pitch to which breathing is entrained to low frequencies over a 15 minute interval. the meditative relaxation involves passive attention to natural breathing for the same duration. participants will perform these breathing exercises daily at home for four weeks. before and after the intervention, respiratory, cardiovascular, and urinary endogenous digitalis-like factors will be systematically recorded to determine the extent to which chronic neuroendocrine changes underlie the reductions in blood pressure.

Eligibility criteria:
inclusion criteria: * over 21 years * systolic blood pressure 130-160 or diastolic blood pressure 85-100 exclusion criteria: * more than one antihypertensive medication * beta blockers, angiotensin converting enzyme inhibitors or angiotensin receptor blockers * history of coronary artery disease, heart failure, stroke, angina or coronary revascularization * kidney disease, defined as plasma creatinine \> 1.5mg/dl * diabetes, defined by insulin or oral hypoglycemic medication or blood sugar \> 126mg/dl * pulmonary disease, defined as chronic obstructive pulmonary disease, bronchitis, asthma, or use of inhaler * upper respiratory infection during past 30 days * medication that affects central nervous system function * steroid use * current pregnancy or lactation within past six months * current birth control medication or hormone replacement therapy * condition that in the judgment of the principal investigator is incompatible with the research study

Keywords: hypertension high blood pressure meditation
impact of whole-body vibration training on muscle flexibility and fatigue after lower extremity thermal burn injury

Conditions: Lower Extremity Burns

Summary: tight hamstring muscles limit the anterior tilt of the pelvis in spinal flexion resulting in aggravated muscle and ligamentous tension in the lumbar region which leads to significantly higher compressive loads on the lumbar spine. other postural changes associated with tightness of the hamstrings can influence the sacroiliac joint stability in an indirect way. hence, flexibility of hamstring muscles is crucial for overall well-being and optimal physical fitness.


Eligibility criteria:
inclusion criteria: 1. patients with a deep second-degree thermal burn of the lower extremity, 35%-40% total body surface area (tbsa) of burn as measured with the rule of nine, after six weeks from the injury or complete wound healing. 2. patients with 20 to 50 years old. 3. absence of any neurological disorder i.e.: stroke, ataxia, or parkinsonism. exclusion criteria: 1. patients with open wounds. 2. patients with recent fractures. 3. patients with severe obesity bmi ≥40. 4. patients with cardiorespiratory disorders. 5. patients with bone disease, joint replacement, and traumatic spine history since last year. in order to apply the inclusion and exclusion criteria, all cases will be subjected to an interview and assessment. those subjects who will be eligible to take part in the study will sign an informed consent before participation in the study.

Keywords: burn flexibility muscle fatigue emg
accommodative relief for uncomfortable non-presbyopes

Conditions: Asthenopia

Summary: this study will determine how multifocal contact lens correction affects symptoms of discomfort and asthenopia in a group of myopic contact lens wearers in the non-presbyopic age range (ages 30-40 years).

the purpose of this study is to determine how multifocal contact lenses affect contact lens comfort in non-presbyopic contact lens wearers. current soft contact lens wearers who have symptoms of discomfort in their contact lenses will be recruited. each subject (n = 84) will wear a single vision soft contact lens (ultra single vision spherical lens) for two weeks and a low add power multifocal (ultra for presbyopia) for two weeks. half of the subjects will wear the single vision lens first, and half of the subjects will wear the multifocal lens first. initial lens group will be chosen randomly. subjects will complete surveys that assess their vision and comfort which each lens, and ocular surface and accommodative/binocular vision status will be evaluated at the initial dispense and after wearing each lens for two weeks.

Eligibility criteria:
inclusion criteria: * visual acuity of 20/25 or better in both eyes with habitual contact lenses * -0.75 d or more myopic in both eyes * -0.75 d or less astigmatism in both eyes * current single vision contact lens wearer who does not require a reading aid * cldeq-8 score of 12 or more points with habitual contact lenses * no history of ocular surgery or medication * reports digital device use of at least 3 hours per day * no significant signs of dry eye (grade 1 or less ocular surface staining, schirmer score of 7 mm or more, and tear break up time of 7 seconds or more in bother eyes) * no significant binocular vision disorders in both eyes (eso or exophoria of 4 prism diopters or less at distance and near, near point of convergence of 6 mm or less, no history of strabismus or patching)

Keywords: contact lens multifocal accommodation presbyopia
a feedback-enabled magnetic device for temporary management of blepharoptosis

Conditions: Blepharoptosis; Device Usability

Summary: to develop a feedback-enabled magnetic device for management of blepharoptosis and evaluate its efficacy and safety, including the gain of palpebral fissure height, visual field obstruction, blurred vision, foreign body sensation over the cornea, burning or hot sensation over facial skin, and erythema or pruritus over the eyelid, by performing a human trial on patients with blepharoptosis.

the feedback-enabled magnetic device primarily comprises 2 matched pairs of one near-infrared light-emitting diode and one photodiode sensor, a magnetic actuator, an iron sheet (for affixing to the paralytic upper eyelid), and a biosignal acquisition module along with a power supply unit providing a wired connection with optical sensors and a magnetic actuator. before the study, the differences between the affected and unaffected palpebral fissure heights were directly measured using a ruler. during the test after using the device, the distance of the paralytic eyelid lift was documented and the corrected distance (gain) of the paralytic upper eyelid was calculated. the efficacy and safety of the device were assessed. the efficacy was evaluated according to the symmetrical blinks and gain of paralytic eyelid lifts. subjective sensation and complications were assessed by visual field obstruction, blurred vision, foreign body sensation over the cornea, burning or hot sensation over facial skin, and erythema or pruritus over the eyelid. after the completion of the study procedure, the eyelid skin integrity, subjective sensation and discomfort were examined. outcomes in the management of blepharoptosis of diverse etiologies using a feedback-enabled magnetic device will be demonstrated. differences in outcomes between patients managed using the device and those who underwent surgery will be presented.

Eligibility criteria:
inclusion criteria: * patients with ptosis; they are capable of understanding and complying with protocol requirements * aged 18 years old or older exclusion criteria: * upper eyelid scar, contracture, or fibrosis due to previous surgical intervention(s) * patients with psychiatric (or mental) disorders; they are unable to cooperate or follow the study procedure * children younger than 18 years of age

Keywords: blepharoptosis blink restoration magnetic device oculomotor nerve palsy ptosis
hair-sparing whole brain radiotherapy

Conditions: Brain Metastases; Small Cell Lung Cancer

Summary: up to 10% of patients with cancer will develop symptomatic brain metastases. given this limited survival it is important to consider quality of life (qol) when treating these patients. whole brain radiotherapy (wbrt) can increase survival to 6 month. however, wbrt itself has been shown to reduce qol by increasing drowsiness, leg weakness and hair loss in patients with brain metastases. both fatigue and hair loss were reported to have the largest decline in qol scores when wbrt is used in the prophylactic setting in small cell lung cancer. recent technological improvements in patient positioning and treatment planning will allow us to treat the whole brain with reduced margins, allowing better sparing of the scalp. in view of the large impact of hair loss on quality of life, the investigators hypothesize to see an improved quality of life with scalp sparing techniques. study hypothesis: volumetric arc therapy results in a reduced hair loss and a subsequent clinically important improvement in qol.


Eligibility criteria:
inclusion criteria: * brain metastases * age ≥ 18 years. * signed informed consent * recursive partitioning analysis (rpa) class iii patients * recursive partitioning analysis (rpa) class i-ii patients and \>3 brain metastases * patients with small cell lung cancer extended disease eligible for prophylactic whole-brain radiotherapy (wbrt). exclusion criteria: * previous whole brain radiotherapy

Keywords: patients treated with whole brain radiotherapy in the setting of brain metastases patients treated with whole brain radiotherapy in the prophylactic treatment for small cell lung cancer (extended disease).
safety and efficacy study of novorapid™ in patients with coexisting diabetes and kidney disease

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Chronic Kidney Disease

Summary: this study is conducted in asia. the aim of this observational study is to investigate the clinical safety profile and effectiveness while using sc novorapid™ (insulin aspart) in patients with coexisting diabetes and kidney disease under normal clinical practice conditions in india.


Eligibility criteria:
inclusion criteria: * any subject with coexisting kidney disease and type 1 or type 2 diabetes is eligible for the study, including: newly-diagnosed subjects, insulin naïve and subjects who have received insulin or an insulin analogue before * subjects with kidney disease (stage i-iv) including transplant patients will be eligible for the study, if initiated with novorapid™" exclusion criteria: * subjects who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit * subjects with stage v of chronic kidney disease * subjects who previously enrolled in this study * known or suspected allergy to trial product(s) or related products
erector spinae catheter versus paravertebral catheter for postoperative analgesia in cancer patients post mastectomies

Conditions: Post Operative Pain

Summary: all patients admitted in national cancer institute, cairo university for breast surgeries will be investigated for inclusion criteria in the current study. and will be enrolled if fulfilled the criteria into 2 groups .70 patients will be included in this prospective randomized study. the patients will be allocated into two groups: the espb group (group e, n = 35) , and the paravertebral group (group p, n =35) * all patients will do ultrasound-guided espb for group e and pvb for group p before receiving general anesthesia * postoperatively patients in both groups will receive intravenous morphine 3 mg as rescue analgesic

* 70patients will be included in this prospective randomized study. the patients will be allocated into two groups: the espb group (group e, n = 35) , and the paravertebral group (group p, n =35) * all patients will do ultrasound-guided espb for group e and pvb for group p before receiving ga * postoperatively patients in both groups will receive intravenous morphine 3 mg as rescue analgesic. * random numbers were generated using a computer-generated randomization code and were sealed in an opaque envelope. randomization was conducted by a person who was not involved in the study. * an independent observer who was blind to the group assignment checked the intraoperative and postoperative data. * vas pain score immediately postoperative and at 2,4,6, 8,12,18,24,36 ,48hrs.postoperative.

Eligibility criteria:
inclusion criteria: .physical status asa ii. . patients (age 20-70yrs) scheduled for breast surgeries for breast cancer under general anesthesia exclusion criteria: .history of psychological disorders. * known sensitivity or contraindication to local anesthetics. * localized infection at the site of block. * patients with coagulopathy or an (inr ≥ 2)
the effect of sirolimus on immunizations during the treatment of kaposiform hemangioendothelioma

Conditions: Kaposiform Hemangioendothelioma

Summary: to research and explore the antibody protection and immune memory after vaccination in children with khe during sirolimus administration. to explore the feasibility (safety and efficacy) of vaccination in a timely manner during the administration of sirolimus in children with khe. to search for back-up plans for vaccination regimens for khe patients taking sirolimus in children who do not respond to primary vaccination.

children with khe have an early onset. khe usually occurs in infants and young children less than 1 year old, of which neonates account for about 38.5%-60% of all cases. due to the immunosuppressive effect of sirolimus, the vaccination was usually suspended after taking it, and children would be in a state of no immune protection. these children are at greatly increased risk of exposure to microorganisms and consequent infection. therefore, it is necessary to vaccinate them against infectious diseases. however, vaccination with live vaccines has the potential to cause severe infections through reversion of the vaccine strain to a pathogenic form. moreover, studies have also shown that protective antibodies are severely affected in transplant patients taking immunosuppressive drugs and in patients with solid tumors after chemotherapy. loss of immune memory is very common, and marked deficits in b cell function and humoral immunity can persist even for years.

Eligibility criteria:
inclusion criteria: * case groups: * khe patients treated with sirolimus. * after immunoglobulin and flow cytometry assays, as well as outpatient evaluation and assessment, those participants will be vaccinated with live attenuated vaccines or inactivated vaccines in a timely order according to the advice. * control groups: * healthy children with no immune deficiencies. * participants are vaccinated according to the national immunization program in a timely manner. * participants are matched to the case group according to age. exclusion criteria: * hbsag, hbeag positive, or other active infectious diseases; * history of immunodeficiency or low immunoglobulin levels; * autoimmune disease or fever during blood collection; * use of other medication or surgery; * suffering from other bleeding disorders; * suffering from other solid tumors or hematological tumors, etc.; * withdraw informed consent.

Keywords: following national vaccination program sirolimus
virtual reality system to increase access to exposure therapy for anxiety and ocd

Conditions: Anxiety; Obsessive Compulsive Disorder

Summary: cognitive behavioral therapy with fear provoking exposures is the most effective therapy for anxiety disorders. investigators aim to enhance this therapy with the use of virtual reality exposures and to make therapy more available and accessible for patients with anxiety disorders. the societal benefit of increased access to therapy is that, if successful, it will increase the number of patients who receive appropriate treatment for an anxiety disorder.

twenty children with cads or ocd who have received less than 3 treatment sessions and a parent will be recruited to pilot the vr system. participants will be identified through the mayo clinic pediatric anxiety disorders clinic. each patient will participate in a single (up to) 2-hour visit. during the first 30 minutes the patient and parent will be introduced to the vr system and the rationale for this feasibility study. next, a therapist will lead the patient through exposure exercises using the vr system for up to 30 minutes. during the next period, up to 30 minutes, the therapist will go to a different room and the patient, with support from their parent, will complete exposure exercises using the vr system that the therapist directed them to complete. during the exposures the interviewer will observe, code and record the patient's interaction with the vr system. for the remaining time (up to 30 minutes) the interviewer will interview the patient about his or her experience with the vr system and then will ask for observations and opinions from the parent.

Eligibility criteria:
inclusion criteria: 1. age 7 to 12 2. primary diagnosis of anxiety, generalized anxiety disorder, social phobia, separation anxiety and/or ocd exclusion criteria: 1. history of and/or current diagnosis of: psychosis, autism, bipolar disorder, mental retardation, oppositional defiant disorder, ptsd, selective mutism or major depressive disorder. 2. current suicidality or recent suicidal behavior 3. parent to be involved in study who is unable to adequately participate due to intellectual or psychiatric difficulties 4. starting or changing the dosage of a psychiatric medication in the last 2 months

Keywords: anxiety ocd obsessive compulsive disorder generalized anxiety social phobia separation anxiety gad youth teen therapy
prognostic value of soluble urokinase plasminogen activation receptor (supar) to rule out complications in patients admitted in emergency department for acute abdominal pain.

Conditions: Soluble Urokinase Plasminogen Activation Receptor; Abdominal Pain; Emergency Department; Mortality

Summary: soluble urokinase plasminogen activation receptor (supar) is a validated biomarker with applications in the study of inflammation and infection. elevated levels of supar have recently been linked to a higher mortality in patients suffering from undifferentiated sepsis, pneumonia, and more recently, covid-19 infection. large randomized controlled trials have been conducted on patients admitted to the emergency department (er), regardless of the reason for admittance. these studies have stratified risk based on three cutoffs at initial measurement: * low risk : \< 3 ng/ml * intermediate risk : entre 3 et 6 ng/ml * high risk : \> 6 ng/ml low levels of supar are associated with low risk of mortality in the short and long term in patients presenting to the ed, no matter the reason for admittance. risk stratification could be an added decision-making tool for clinicians to comfort hospital discharge. to the best of our knowledge, there is no available data on the added value of supar for predicting mortality in abdominal sepsis and abdominal pain. abdominal pain is responsible for 10 to 30 % of er admissions. consequently, abdominal pain is then responsible for roughly 10 % of admissions into medical and surgical wards. mortality varies depending on patient factors. mortality is usually stratified on age. in patients under 50 years of age, it is near 8%, but it reaches 19 % in patients over 50. diagnostic accuracy also decreases drastically with age, reaching approximately 30 % patients over 75. taking this into account, integrating a measure of supar levels into the current standard of care could stratify the risk of complications in patients admitted to the er with abdominal pain.


Eligibility criteria:
inclusion criteria: patients : * over 18 years of age * presenting to the ed with abdominal pain for over an hour * classified as category 2 or above on the cimu or french severity scale * necessitating bloodwork at the discretion of the consulting physician * who gave his non-opposition after clear and fair information on the study exclusion criteria: patients : * with pain evocative of kidney stones * with a chronic inflammatory disease: hiv infection, inflammatory bowel disease, rheumatoid arthritis, cancer * chronic renal disease * under hospice care * intubated * unstable hemodynamically * transferred from a secondary care facility and having undergone previous bloodwork * patient unable to understand the information and to give his non-objection * under guardianship, curatorship or subordination; * benefiting from enhanced protection, namely: minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in an establishment health or social, adults under legal protection